{"id":"spironolactone-drug","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"10-15","effect":"Gynecomastia"},{"rate":"5-10","effect":"Menstrual irregularities"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Dizziness"},{"rate":"2-5","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL1393","moleculeType":"Small molecule","molecularWeight":"416.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that binds to mineralocorticoid receptors in the collecting duct of the nephron. By blocking aldosterone's effects, it prevents sodium reabsorption and potassium excretion, leading to increased urine output and reduced blood volume and blood pressure. It is also used for its anti-fibrotic and anti-inflammatory properties in heart failure and other conditions.","oneSentence":"Spironolactone blocks aldosterone receptors in the kidney to increase sodium and water excretion while retaining potassium.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:53.452Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Primary hyperaldosteronism"},{"name":"Edema associated with cirrhosis or nephrotic syndrome"},{"name":"Resistant hypertension"}]},"trialDetails":[{"nctId":"NCT04760717","phase":"PHASE2","title":"Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-03-19","conditions":"Intracerebral Hemorrhage, Ischemic Stroke, Spironolactone","enrollment":160},{"nctId":"NCT01712620","phase":"PHASE2","title":"Spironolactone for Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-01-10","conditions":"Pulmonary Arterial Hypertension","enrollment":70},{"nctId":"NCT06678685","phase":"PHASE2, PHASE3","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-30","conditions":"NCOR Gene Mutations, Spironolactone, ASD","enrollment":2},{"nctId":"NCT07483151","phase":"","title":"Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","enrollment":110},{"nctId":"NCT07483177","phase":"PHASE1, PHASE2","title":"HEART: Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-05","conditions":"Thoracic Aortic Aneurysm","enrollment":50},{"nctId":"NCT07473895","phase":"PHASE2","title":"Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT04582383","phase":"PHASE4","title":"Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-30","conditions":"Acne","enrollment":350},{"nctId":"NCT07431216","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression","status":"NOT_YET_RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2026-04-01","conditions":"Histopathology Confirmed Supratentorial GBM at First Recurrence, IDHwt GBM, IDHm Grade 4 Astrocytoma","enrollment":68},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT05807139","phase":"PHASE1","title":"Spironolactone in Alcohol Use Disorder (SAUD)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-07-13","conditions":"Alcohol Use Disorder","enrollment":20},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT07415811","phase":"NA","title":"Spironolactone and XPB-1 Integrity in the TFIIH Complex","status":"ENROLLING_BY_INVITATION","sponsor":"University of Sao Paulo General Hospital","startDate":"2024-07-24","conditions":"HIV","enrollment":12},{"nctId":"NCT03593317","phase":"PHASE2","title":"Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-20","conditions":"Arrhythmogenic Right Ventricular Dysplasia","enrollment":120},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT06004830","phase":"PHASE2","title":"Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Alcohol Use Disorder, Hiv","enrollment":30},{"nctId":"NCT07331220","phase":"NA","title":"Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-12-30","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":310},{"nctId":"NCT07328230","phase":"NA","title":"Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-08-01","conditions":"Idiopathic Hyperaldosteronism, Hyperaldosteronism","enrollment":172},{"nctId":"NCT03429946","phase":"PHASE4","title":"Hypoglycemia and Autonomic Nervous System Function-B","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-07-17","conditions":"Hypoglycemia, Healthy","enrollment":28},{"nctId":"NCT07304817","phase":"PHASE2","title":"Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-02","conditions":"CKD, Cardiovascular Diseases, Heart Failure","enrollment":100},{"nctId":"NCT07285187","phase":"","title":"Venous Congestion And Delirium After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative, Venous Congestion, Postoperative Delirium (POD)","enrollment":120},{"nctId":"NCT05561361","phase":"","title":"The Effect of SAAE on Vascular Endothelial Function in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-10-01","conditions":"Primary Aldosteronism","enrollment":200},{"nctId":"NCT04251780","phase":"","title":"Tissue K+ in Primary Hyperaldosteronism","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2018-01-01","conditions":"Primary Hyperaldosteronism, Electrolyte Disturbance","enrollment":21},{"nctId":"NCT04633005","phase":"PHASE2","title":"Polypill Strategy for Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-11-15","conditions":"Heart Failure","enrollment":212},{"nctId":"NCT07235891","phase":"PHASE4","title":"Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-11-20","conditions":"Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07232277","phase":"","title":"Venous Congestion and Cardiac Surgery-Associated Acute Kidney Injury","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-10-15","conditions":"Intraoperative, Venous Congestion, Cardiac Surgery-associated Acute Kidney Injury","enrollment":114},{"nctId":"NCT04980716","phase":"PHASE3","title":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Non-small Cell Lung Cancer, Cardiovascular Complication","enrollment":524},{"nctId":"NCT04522739","phase":"PHASE4","title":"Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-09-06","conditions":"Mild Cognitive Impairment, Alzheimer Disease","enrollment":25},{"nctId":"NCT07041281","phase":"PHASE2","title":"Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-16","conditions":"Preeclampsia, Gestational Hypertension","enrollment":204},{"nctId":"NCT05014087","phase":"PHASE2","title":"Digoxin In Treatment of Alcohol Associated Hepatitis","status":"TERMINATED","sponsor":"Yale University","startDate":"2021-10-08","conditions":"Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders","enrollment":23},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT01552044","phase":"PHASE1, PHASE2","title":"Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2012-01","conditions":"Central Serous Chorioretinitis","enrollment":17},{"nctId":"NCT07137364","phase":"","title":"Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2022-05-01","conditions":"Primary Aldosteronism, Hypertension","enrollment":350},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":"Polymorphic Ventricular Tachycardia, Heart Failure","enrollment":118},{"nctId":"NCT05676684","phase":"PHASE2, PHASE3","title":"Dapagliflozin With or Without Spironolactone for HFpEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2022-09-15","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":108},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT03068910","phase":"EARLY_PHASE1","title":"Hyperandrogenemia and Altered Day-night LH Pulse Patterns","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2016-07-21","conditions":"Hyperandrogenism, Polycystic Ovary Syndrome, Puberty","enrollment":32},{"nctId":"NCT04723862","phase":"EARLY_PHASE1","title":"Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2021-11-12","conditions":"Hyperandrogenism, Polycystic Ovary Syndrome, Puberty","enrollment":32},{"nctId":"NCT06247267","phase":"","title":"The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2021-03-09","conditions":"Hypogonadism, Gender Identity Dysphoria","enrollment":75},{"nctId":"NCT04676646","phase":"PHASE4","title":"Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-08","conditions":"Hyperkalaemia, Heart Failure With Reduced Ejection Fraction","enrollment":366},{"nctId":"NCT07020104","phase":"NA","title":"The Role of Skin Sodium Accumulation in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-01-07","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT04901975","phase":"PHASE1, PHASE2","title":"Fibrosis and the Fontan","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-02-11","conditions":"Single-ventricle","enrollment":145},{"nctId":"NCT03929718","phase":"EARLY_PHASE1","title":"Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Piedmont Healthcare","startDate":"2019-04-24","conditions":"AFib","enrollment":50},{"nctId":"NCT05501080","phase":"NA","title":"The Effect of SAAE on Ventricular Remodeling in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-09-01","conditions":"Primary Aldosteronism","enrollment":112},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT05797558","phase":"NA","title":"Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2023-04-28","conditions":"Primary Hyperaldosteronism Due to Adrenal Adenoma","enrollment":80},{"nctId":"NCT04727073","phase":"PHASE3","title":"Spironolactone in the Treatment of Heart Failure","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-01","conditions":"Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction","enrollment":743},{"nctId":"NCT03576755","phase":"PHASE1, PHASE2","title":"Spironolactone Therapy In Young Women With NASH","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-01-09","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":20},{"nctId":"NCT04283656","phase":"PHASE1","title":"Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-01-04","conditions":"Transgender Health, Gender Dysphoria, Transgender Women","enrollment":8},{"nctId":"NCT06641284","phase":"","title":"Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone","status":"COMPLETED","sponsor":"Ahmad Abdullah Salawi","startDate":"2023-10-01","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II","enrollment":509},{"nctId":"NCT06205407","phase":"PHASE1","title":"A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-26","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT03020303","phase":"PHASE3","title":"Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-07-07","conditions":"Endstage Renal Disease","enrollment":2538},{"nctId":"NCT05092984","phase":"PHASE3","title":"Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-06-22","conditions":"Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05933265","phase":"PHASE1, PHASE2","title":"Study of LP-184 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-06-09","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, GBM","enrollment":175},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT04142788","phase":"PHASE4","title":"RELieving Increasing oEdema Due to Heart Failure","status":"TERMINATED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2020-08-26","conditions":"Heart Failure，Congestive","enrollment":19},{"nctId":"NCT06377449","phase":"NA","title":"Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-05-15","conditions":"Ischemic Heart Disease, Aortic Stenosis, Severe, Aortic Insufficiency","enrollment":186},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06523465","phase":"PHASE4","title":"Statin Combined with Amlodipine Treats Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2024-09-10","conditions":"Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist","enrollment":180},{"nctId":"NCT05318755","phase":"","title":"China Gender-affirming Hormone Therapy Study","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2022-04-16","conditions":"Transgender, Gender Incongruence","enrollment":240},{"nctId":"NCT02901184","phase":"PHASE3","title":"Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2017-11-23","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2000},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT03048825","phase":"PHASE3","title":"Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-02-01","conditions":"ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction","enrollment":7264},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT04331691","phase":"PHASE4","title":"Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-11-16","conditions":"Resistant Hypertension","enrollment":118},{"nctId":"NCT04100083","phase":"PHASE4","title":"Spironolactone for Hidradenitis Suppurativa","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2020-09-21","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03874338","phase":"","title":"CLEAR SYNERGY Neutrophil Substudy","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-03-04","conditions":"Neutrophils.Hypersegmented | Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction","enrollment":322},{"nctId":"NCT06091475","phase":"NA","title":"Therapy to Maintain Remission in Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-12-02","conditions":"Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies","enrollment":50},{"nctId":"NCT03953209","phase":"PHASE1","title":"Spironolactone for the Treatment of Melasma","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2020-03-05","conditions":"Melasma","enrollment":""},{"nctId":"NCT06457074","phase":"PHASE4","title":"Finerenone for Patients With Primary Aldosteronism (FAIRY)","status":"RECRUITING","sponsor":"Qifu Li","startDate":"2024-06-04","conditions":"Primary Aldosteronism","enrollment":306},{"nctId":"NCT06579053","phase":"PHASE1","title":"Bioequivalence Study of Spironolactone Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"SPH Sine Pharmaceutical Laboratories Co., Ltd.","startDate":"2023-03-22","conditions":"Bioequivalence Study","enrollment":64},{"nctId":"NCT01294319","phase":"PHASE2","title":"Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-01-24","conditions":"Cortisol Resistance, Negative Feedback, ACTH","enrollment":51},{"nctId":"NCT06499948","phase":"PHASE4","title":"Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)","status":"RECRUITING","sponsor":"Stefan Lujinschi","startDate":"2024-02-26","conditions":"Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy","enrollment":34},{"nctId":"NCT03344159","phase":"PHASE4","title":"Spironolactone Therapy in Chronic Stable Right HF Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-04-01","conditions":"Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2","enrollment":15},{"nctId":"NCT04643691","phase":"PHASE2","title":"Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2020-09-11","conditions":"COVID-19, ARDS","enrollment":78},{"nctId":"NCT05924620","phase":"PHASE4","title":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2023-06-21","conditions":"Primary Aldosteronism","enrollment":60},{"nctId":"NCT06413082","phase":"PHASE3","title":"Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2021-02-15","conditions":"Hypertension, Genetic Predisposition, Drug Effect","enrollment":38},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT03652623","phase":"PHASE1, PHASE2","title":"Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study","status":"COMPLETED","sponsor":"Hektoen Institute for Medical Research","startDate":"2018-07-23","conditions":"HIV/AIDS, Gender, Behavior and Behavior Mechanisms","enrollment":49},{"nctId":"NCT06233695","phase":"","title":"Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-10-15","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II","enrollment":100},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT06035978","phase":"PHASE4","title":"Determination of Drug Levels for Pharmacotherapy of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-03","conditions":"Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction","enrollment":100},{"nctId":"NCT06204640","phase":"PHASE3","title":"SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-03-01","conditions":"Atrial Fibrillation Recurrent","enrollment":580},{"nctId":"NCT06164379","phase":"PHASE4","title":"Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-12-16","conditions":"Primary Aldosteronism","enrollment":150},{"nctId":"NCT01422759","phase":"NA","title":"Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2016-12-09","conditions":"Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome","enrollment":20},{"nctId":"NCT04075149","phase":"EARLY_PHASE1","title":"Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2019-12-18","conditions":"Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder","enrollment":24},{"nctId":"NCT03777319","phase":"PHASE1","title":"Spironolactone Versus Prednisolone in DMD","status":"TERMINATED","sponsor":"Kevin Flanigan","startDate":"2018-12-05","conditions":"Muscular Dystrophy, Duchenne","enrollment":2},{"nctId":"NCT01848639","phase":"PHASE3","title":"ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2013-06","conditions":"End Stage Renal Failure on Dialysis","enrollment":823},{"nctId":"NCT05287100","phase":"NA","title":"To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-01-01","conditions":"Cirrhosis, Liver","enrollment":35},{"nctId":"NCT04367051","phase":"NA","title":"Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":62},{"nctId":"NCT06021860","phase":"PHASE4","title":"A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients","status":"UNKNOWN","sponsor":"CMP Development, LLC","startDate":"2024-06","conditions":"Edema Due to Heart Failure or Cirrhosis","enrollment":96},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldactone®","Spironolactone"],"phase":"marketed","status":"active","brandName":"Spironolactone (drug)","genericName":"Spironolactone (drug)","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Spironolactone blocks aldosterone receptors in the kidney to increase sodium and water excretion while retaining potassium. Used for Heart failure with reduced ejection fraction, Hypertension, Primary hyperaldosteronism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}